Holen Sie sich die Stockscreener-App
3.52
0.00%
0.00
Handel nachbörslich:
3.52
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Analyst Upgrade: Why is Aclaris Therapeutics Inc stock going upMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Wrap: Why is Aclaris Therapeutics Inc stock going up2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - barchart.com
Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life - Quiver Quantitative
Experimental eczema pill cut disease severity 77% in 12-week trial - Stock Titan
Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting - MyChesCo
Vanguard (ACRS) Amends Schedule 13G; Reports 0 Shares After Realignment - Stock Titan
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Published on: 2026-03-26 16:32:45 - baoquankhu1.vn
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis - MyChesCo
Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst - MarketBeat
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Published on: 2026-03-22 04:18:49 - baoquankhu1.vn
Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data - Investing.com
Deep Track Capital, LP Acquires Significant Stake in Aclaris Therapeutics Inc - GuruFocus
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The Manila Times
Aclaris Therapeutics Announces ePoster Presentation on Phase 2a Trial Results of ATI-2138 for Moderate-to-Severe Atopic Dermatitis at AAD Annual Meeting 2026 - Quiver Quantitative
New eczema trial results from Aclaris will debut at dermatology meeting - Stock Titan
Aclaris stock maintained at Buy by H.C. Wainwright on trial progress - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
Aclaris completes enrollment in atopic dermatitis trial By Investing.com - Investing.com Canada
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings - MarketBeat
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bitget
Aclaris Therapeutics completes enrollment in phase 2 trial of bosakitug (ATI-045) in atopic dermatitis - marketscreener.com
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis - TradingView
Aclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026 - Quiver Quantitative
109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan
Deep Track entities hold 9.35M Aclaris shares (ACRS) — 7.01% stake - Stock Titan
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Aclaris Therapeutics Raises $20 Million in Equity Financing - The Globe and Mail
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aclaris Therapeutics (NASDAQ: ACRS) sells 5.7M shares to raise $20M - Stock Titan
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):